• Glaukos reports positive study results for iDose TR, iStent infinite

    6 days ago - By Healio

    Two IOP reduction methods from Glaukos showed favorable results and safety profiles in recent trials, according to company press releases.
    The iDose TR sustained-release travoprost implant provided substantial IOP reductions in an interim analysis of an ongoing 36-month phase 2b clinical trial, while the iStent infinite trabecular micro-bypass system showed substantial mean diurnal IOP reduction through 12 months.
    The iDose TR was evaluated in a 154-subject, multicenter, randomized, double-masked trial designed to evaluate a single administration of one of two iDose TR models compared with
    Read more ...